Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Davey B. Daniel

Hematology Oncology | Hematology | Oncology
Tennessee Oncology PLLC
4645 Battlefield Pkwy, 
Ringgold, GA 
Accepting New Patients
Offers Telehealth
Distinguished in WT1-Related Wilms Tumor Syndromes
Tennessee Oncology PLLC
4645 Battlefield Pkwy, 
Ringgold, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Davey Daniel is a Hematologist Oncology specialist and a Hematologist in Ringgold, Georgia. Dr. Daniel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Dehydration, and Non-Small Cell Lung Cancer (NSCLC). Dr. Daniel is currently accepting new patients.

His clinical research consists of co-authoring 35 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Memorial Healthcare System, Inc
Affiliate Of Vitruvian Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

TENNESSEE ONCOLOGY PLLC
4645 Battlefield Pkwy, Ringgold, GA 30736
Other Locations
TENNESSEE ONCOLOGY PLLC
1032 Mccallie Ave, Suite 200, Chattanooga, TN 37403

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor
A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Enrollment Status: Completed
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, GSK3359609, Ipilimumab, Niraparib, Dostarlimab, Cobolimab
Study Phase: Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Canakinumab
Study Phase: Phase 3
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drugs: Aldoxorubicin, Topotecan
Study Phase: Phase 2
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2024
Intervention Type: Drug
Study Drugs: Efineptakin alfa, Atezolizumab
Study Phase: Phase 2
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drugs: VS-6766, VS-6766+Defactinib
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Enrollment Status: Terminated
Publish Date: August 16, 2023
Intervention Type: Drug
Study Drug: KRT-232
Study Phase: Phase 2
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials

35 Total Publications

A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
Journal: The oncologist
Published: December 18, 2024
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hosam M. Saad-Naguib
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Hosam M. Saad-Naguib
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

1504 N Thornton Ave, Suite 102, 
Dalton, GA 
 (14.9 miles away)
706-226-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hosam Saad-Naguib is a Hematologist Oncology specialist and a Hematologist in Dalton, Georgia. Dr. Saad-Naguib is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Colorectal Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Saad-Naguib is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Edward R. Arrowsmith
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Edward R. Arrowsmith
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

2333 Mccallie Ave, 
Chattanooga, TN 
 (8.5 miles away)
423-493-1690
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edward Arrowsmith is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Arrowsmith is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Dehydration, and Familial Colorectal Cancer. Dr. Arrowsmith is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Robert M. Graham
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Robert M. Graham
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

605 Glenwood Dr, Suite 200, 
Chattanooga, TN 
 (8.6 miles away)
423-698-1844
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Graham is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Graham is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Childhood Iron Deficiency Anemia, Familial Pancreatic Cancer, Paget Disease of the Breast, and Dehydration. Dr. Graham is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daniel's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 54 Advanced Conditions
View All 151 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile